Jiangsu Hengrui Medicine Company Ltd.

Shanghai Hengrui Pharmaceutical Co., Ltd.

Sandisk Technologies Inc.

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Guiyang Jiang

Ying Zhang

Jianyan Xu

Weikang Tao

Lianshan Zhang

Ling L Zhang

Yali Wang

Yayuan Fu

Dongbing Cui

Jiajian Liu

Jindong Liang

Ai-wen Wang

Dong Ma

Wei-Chun Shen

Junzhuan Qiu

Yu-Mei Chen

Ziyong Sun

Jiping Zha

Jingping Wei

Bolei Qu

A data storage device includes a substrate including a number of contact pads and a number of passive component packages coupled to the contact pads. The data storage device further includes a memory controller coupled to the substrate, and one or more NAND die stacks coupled to the substrate and in electrical communication with the memory controller. One or more of the passive component packages include a first passive component, a second passive component electrically connected to the first passive component, and a first terminal coupled to the first passive component. The passive component packages further include a second terminal coupled to the second passive component, and a third terminal coupled to a common node of the first passive component and the second passive component.

Monolithic surface mount passive component

Provided are an anti-c-Met antibody or an antigen binding fragment thereof, and an anti-c-Met antibody-cytotoxic drug conjugate, wherein the antibody or antigen binding fragment thereof is a chimeric antibody or a humanized antibody. Also provided are pharmaceutical compositions containing the humanized anti-c-Met antibody or antigen binding fragment thereof, the antibody-cytotoxic drug conjugate, or pharmaceutically acceptable salts or solvents thereof, that are used in the treatment of cancer.

Anti-c-Met antibody and anti-c-Met antibody-cytotoxic drug conjugate and pharmaceutical use thereof

The present invention relates to a new toxin and a method for preparing an intermediate thereof. In particular, the present invention relates to a new toxin and a method for preparating intermediates of Formula (III) and Formula (IV) thereof, and a preparation method for synthesizing what is shown in general formula (I). The method comprises subjecting a chiral compound shown in general formula (III) to a series of protecting group additions, protecting group removal and amidation so as to obtain a compound as shown in general formula (I). The present method has the advantages of mild reaction conditions, simple operation, high optical purity and high synthetic yield, and thus is suitable for large-scale production. 

Toxin and method for preparing intermediate thereof

Growing community of inventors

Shanghai, China

Guiyang Jiang